Literature DB >> 10026821

Vasopressin regulates adrenal functions by acting through different vasopressin receptor subtypes.

E Grazzini1, G Boccara, D Joubert, M Trueba, T Durroux, G Guillon, N Gallo-Payet, L Chouinard, M D Payet, C Serradeil Le Gal.   

Abstract

In mammals, vasopressin is known to be synthesized in the hypothalamus and released in the blood stream at the pituitary level. This neuropeptide is also synthesized and secreted by the adrenal medulla in many species including human. Moreover, agents like acetylcholine and corticotropin releasing factor stimulates its basal secretion. V1a vasopressin receptors are present in the adrenal cortex and are involved in steroids secretion (aldosterone in the zona glomerulosa and glucocorticoids in the zona fasciculata of some species). These receptors are coupled to phospholipase C beta and to dihydropyridine-sensitive calcium channels via heterotrimeric G proteins differing by their sensitivities to pertussis toxin. The adrenal medulla, from many species, exhibits V1a vasopressin receptors. In rat adrenal medulla, functional V1b vasopressin receptors could also be characterized. These receptors stimulate catecholamines secretion via activation of phospholipase C beta and subsequent mobilization of intracellular calcium. The adrenal medulla secretes AVP and exhibits functional vasopressin receptors. The adrenal cortex also possesses functional vasopressin receptors and is in contact with adrenal medulla via "medullary rays". We may thus reasonably conclude that AVP physiologically regulates adrenal gland functions via autocrine/paracrine mechanisms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10026821     DOI: 10.1007/978-1-4615-4871-3_41

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  10 in total

Review 1.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

2.  Adrenal steroid hormones and ethanol self-administration in male rhesus macaques.

Authors:  Christa M Helms; Byung Park; Kathleen A Grant
Journal:  Psychopharmacology (Berl)       Date:  2014-05-01       Impact factor: 4.530

3.  The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy.

Authors:  W S Young; J Li; S R Wersinger; M Palkovits
Journal:  Neuroscience       Date:  2006-10-04       Impact factor: 3.590

4.  Integrated analysis of genome-wide methylation and gene expression shows epigenetic regulation of CYP11B2 in aldosteronomas.

Authors:  Brandi Howard; Yonghong Wang; Paraskevi Xekouki; Fabio R Faucz; Meenu Jain; Lisa Zhang; Paul G Meltzer; Constantine A Stratakis; Electron Kebebew
Journal:  J Clin Endocrinol Metab       Date:  2013-12-11       Impact factor: 5.958

5.  Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist.

Authors:  Rafik Marir; Anne Virsolvy; Kazimierz Wisniewski; Julie Mion; Dominique Haddou; Evelyne Galibert; Zahia Meraihi; Michel G Desarménien; Gilles Guillon
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

Review 6.  The vasopressin Avpr1b receptor: molecular and pharmacological studies.

Authors:  Ja Roper; A-M O'Carroll; Ws Young; Sj Lolait
Journal:  Stress       Date:  2010-09-09       Impact factor: 3.493

Review 7.  Cell-to-cell communication in bilateral macronodular adrenal hyperplasia causing hypercortisolism.

Authors:  Hervé Lefebvre; Céline Duparc; Gaëtan Prévost; Jérôme Bertherat; Estelle Louiset
Journal:  Front Endocrinol (Lausanne)       Date:  2015-04-20       Impact factor: 5.555

8.  AVPR1A distribution in the whole C57BL/6J mouse neonate.

Authors:  Katherine R Day; Alexis Coleman; Maria A Greenwood; Elizabeth A D Hammock
Journal:  Sci Rep       Date:  2020-09-03       Impact factor: 4.379

9.  The renin-angiotensin-aldosterone system in patients with depression compared to controls--a sleep endocrine study.

Authors:  Harald Murck; Katja Held; Marc Ziegenbein; Heike Künzel; Kathrin Koch; Axel Steiger
Journal:  BMC Psychiatry       Date:  2003-10-29       Impact factor: 3.630

10.  Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report.

Authors:  Kyohei Kunizawa; Junichi Hoshino; Hiroki Mizuno; Tatsuya Suwabe; Keiichi Sumida; Masahiro Kawada; Masayuki Yamanouchi; Akinari Sekine; Noriko Hayami; Rikako Hiramatsu; Eiko Hasegawa; Naoki Sawa; Kenmei Takaichi; Shigeru Shibata; Yoshifumi Ubara
Journal:  Case Rep Nephrol Dial       Date:  2018-03-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.